| Budget Amount *help |
¥23,660,000 (Direct Cost: ¥18,200,000、Indirect Cost: ¥5,460,000)
Fiscal Year 2018: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2017: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2016: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2015: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Outline of Final Research Achievements |
Carotenoids are potent antioxidants and anti-inflammatory micronutrients that have the potential to prevent or treat non-alcoholic fatty liver disease (NAFLD). We focused on the efficacy of carotenoid for metabolic syndrome, diabetes, NAFLD and nonalcoholic steatohepatitis (NASH). In this study, our data indicated that carotenoids, such as astaxanthin and lycopene, prevented and reversed NASH or insulin resistance by suppressing oxidative stress and regulating macrophage polarization both in liver and adipose tissue.
In addition, we found that chemokine system fractalkine-CX3CR1 had negative influences on insulin sensitivity by increasing adipose tissue macrophage recruitment. To further investigate the role of CX3CR1 on metabolic syndrome, we generated tissue-specific CX3CR1 knockout mice. The KO mice exacerbated obesity-induced inflammation and insulin resistance, suggesting that it have the potential to be a novel metabolic syndrome model.
|
